1. Home
  2. Directory
  3. Kansas
  4. City
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1760414767

MATTHIAS A SALATHE MD
Prescription History 1760414767
Internal Medicine - Pulmonary Disease in Kansas City, KS


Quality Rating: 91.89 out of 100 score

NPI Status: Active since July 07, 2006

Contact Information

4000 CAMBRIDGE ST
KANSAS CITY, KS
ZIP 66160
Phone: (913) 588-1235

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MATTHIAS A SALATHE MD, an active Pulmonary Disease specialist practicing in Kansas City, KS. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 41 documented patient claims. Among these therapy options, the most frequently utilized medication is Trikafta, which accounts for 29 claims alone.

Medication Index

C
T
No matching medications currently found on file.

Creon

Generic Formulation: Lipase/Protease/AmylaseSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
KS State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills22.5
Peer Average Days Supply591
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $34,652.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,887.69

State Avg Cost Per Claim

$1,859.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains digestive enzymes to help break down and digest fats, starch, and proteins in food. It is used in conditions where the pancreas cannot make or does not release enough digestive enzymes into the small intestines to digest the food (conditions such as chronic pancreatitis, cystic fibrosis, cancer of the pancreas, post-pancreatectomy, post-gastrointestinal bypass surgery).

Trikafta

Generic Formulation: Elexacaftor/Tezacaftor/IvacaftSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 812
KS State Average Benchmarks
Peer Average Claims75.0
Peer Average 30-Day Fills77.8
Peer Average Days Supply2,186
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.3% less volume than the regional standard for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $759,006.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$26,172.63

State Avg Cost Per Claim

$28,103.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product has 2 different tablets. One tablet contains 3 medications (it is a multi-drug): elexacaftor, tezacaftor, and ivacaftor. The other tablet contains only ivacaftor. This product is used to treat cystic fibrosis in certain people (those with an abnormal CFTR gene). It may help to improve breathing, reduce the risk of lung infections, and improve weight gain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MATTHIAS A SALATHE MD provides transparency into local medical care patterns within Kansas City, KS.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.